Abstract
Pathologic complete remission (pCR) after neoadjuvant radiochemotherapy (RTx/CTx) is related to long-term survival for stage III non-small cell lung cancer (NSCLC) patients and is a surrogate marker for local effectiveness. Repopulation is a problem for fast growing tumors and accelerated-hyperfractionation (AHF) has been proven to be superior in SCLC. For NSCLC, data are missing up to now that demonstrate progress over conventionally fractionated (CF) RTx/CTx to lead a way for further treatment optimization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
